CA
ORMP icon

Clearstead Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Clearstead Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-250
Closed -$1K – 1326
2022
Q2 		$1K Hold
250
– – ﹤0.01% 1206
2022
Q1 		$2K Hold
250
– – ﹤0.01% 1221
2021
Q4 		$4K Hold
250
– – ﹤0.01% 1024
2021
Q3 		$5K Buy
+250
New +$4.26K ﹤0.01% 1032

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clearstead Advisors's ORMP Position: Q3 2022 in Review

Clearstead Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 250 shares — an estimated $1K sold.

Clearstead Advisors first reported a position in ORMP in Q3 2021 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

  • Clearstead Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Clearstead Advisors sold 250 Oramed Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Clearstead Advisors first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Clearstead Advisors's Oramed Pharmaceuticals position peaked at $5K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Clearstead Advisors's 13F filing for Q3 2022, filed 15 Nov 2022.